Executives at cash-strapped biotech Lyra Therapeutics are hoping a drastic reduction in headcount will help keep the lights on, alongside other cost-cutting mea 22 May 2024
A new subcutaneous version of the checkpoint blocker Opdivo (nivolumab) could be approved earlier than expected, after the US regular brought forward the date f 22 May 2024
Data have been presented from the NOTUS Phase III study on the use of Dupixent (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD o 21 May 2024
Israeli dermatology company Sol-Gel Technologies has signed an agreement with Beimei Pharma for the commercialization of Twyneo (tretinoin/benzoyl peroxide) in 21 May 2024
US healthcare giant Johnson & Johnson has announced that the Tremfya (guselkumab) QUASAR maintenance study in ulcerative colitis (UC) met its primary endpoint a 21 May 2024
While AstraZeneca’s chief executive Pascal Soriot has been proven right about many of his prior boasts on the company’s future success during his 12-year reign, 21 May 2024
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technolog 21 May 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.